Owner Novartis AG The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services

Inventors Woo, Jung-Hee; Neville Jr., David M.; Hu, Huaizhong; Thompson, Jerry T.; Ma, Shenglin; Digan, Mary Ellen; Hexham, Jonathan Mark

Agent Griffith Hack

Pub. Number AU-B-2001261760

PCT Pub. Number WO01/87982

Priority 09573797 18.05.00 US

Filing date 18 May 2001

Wipo publication date 26 November 2001

Acceptance publication date 29 March 2007

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/02 (2006.01) Antineoplastic agents

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

C07K 14/34 (2006.01) Peptides having more than 20 amino acids

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C07K 19/00 (2006.01) Hybrid peptides

C12N 1/19 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 1/21 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/02 (2006.01) Mutation or genetic engineering - Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion

C12R 1/19 (2006.01)

C12R 1/865 (2006.01)

C12R 1/91 (2006.01)